09.24.26 -- The Unspoken Truth About Cell Therapy Product Understanding

See how automated, closed processing helps improve consistency in hematopoietic stem cell gene therapy manufacturing, supporting higher transduction efficiency and stronger preservation.

Resolve monomers from dimers across AAV serotypes with a breakthrough solution that cuts sample use by up to 90%, accelerates development, and reduces costs—transforming gene therapy workflows.

Evaluate comprehensive analytical data comparing MSC-EV quality metrics across donors, tissues, and production platforms to identify critical manufacturing variables.

Improve 3D spheroid consistency by optimizing cell selection, seeding density, and plate geometry. Examine comparative data to build repeatable, robust assays for drug screening.

Uncontrolled freeze-thaw cycles risk altering bulk drug substances. Uncover controlled technology designed to prevent protein aggregation and protect product stability during bulk storage.

Inaccurate residual DNA tracking threatens final batch quality. Explore how reliable hcDNA monitoring informs critical upstream and downstream decisions to secure compliance and yield targets.

Combining automated sampling, real-time PAT monitoring, and cloud-based analytics converts complex bioprocess data into actionable, predictive intelligence to protect every bioreactor batch.

Navigating cell line safety requires rigorous identity and purity testing. Study assay plans built for every cell bank stage to satisfy regulatory guidelines and maintain high product safety.

A streamlined approach to HPLC sample preparation can cut plastic waste by up to 79%. Find out how reducing consumables simplifies workflows and supports more sustainable, efficient lab operations.

Explore how PCR works, what impacts reaction success, and how to troubleshoot common challenges with expert guidance and real lab examples designed to help you strengthen your PCR skills.

Lonza has further improved its platform process with the creation of engineered plasmids that afford significantly higher titers and productivity levels compared to standard systems.

Choosing the wrong viral vector can compromise your therapy's safety and efficacy. Compare AAV, lentivirus, adenovirus, HSV, and emerging types across key manufacturing and clinical factors.